Lenzetto

Estradiol, the active ingredient in Lenzetto, is an estrogen presented as a 0.025 mg/24 h transdermal patch for transdermal use. It is indicated for relief of moderate to severe vasomotor symptoms associated with menopause and for the prevention of osteoporosis in postmenopausal women.

GNH USA supplies Lenzetto as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with distribution channels that meet EU regulatory standards. The company provides quality‑assured products and supports customers with technical and regulatory assistance through globally.

Lenzetto, an estrogen therapy, is used to manage menopausal vasomotor symptoms and to protect bone health in postmenopausal women. - Vasomotor symptoms of menopause: reduction of hot flashes and night sweats - Postmenopausal osteoporosis: prevention of bone loss and reduction of fracture risk - Estrogen deficiency: improvement of urogenital atrophy and mood symptoms

Lenzetto may cause a range of adverse reactions. Patients should be aware of both frequent and infrequent events.

Common Side Effects: - Skin irritation at the patch site - Nausea - Headache - Breast tenderness

Serious or Rare Side Effects: - Deep vein thrombosis - Pulmonary embolism - Stroke

Before prescribing Lenzetto, clinicians should consider several safety aspects. - Assess cardiovascular risk: evaluate history of thromboembolic events - Screen for estrogen‑dependent neoplasia: avoid use in known breast or endometrial cancer - Monitor liver function: adjust if severe hepatic impairment - Consider bone density: use as part of osteoporosis prevention plan - Avoid in pregnancy: contraindicated in known or suspected pregnancy - Store at room temperature: keep patch in original pouch, protect from moisture and heat

Estradiol can interact with several medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Combined oral contraceptives: increased risk of thromboembolism - Anticoagulants (e.g., warfarin): may reduce anticoagulant effect - Selective estrogen receptor modulators (e.g., tamoxifen): antagonistic effect

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., ketoconazole): increase estradiol plasma levels - CYP3A4 inducers (e.g., rifampin): decrease estradiol plasma levels - Lithium: may increase risk of breast tenderness